GET DAILY SIGNALSInvivyd (IVVD) Q3 2026 Earnings: PEMGARDA Momentum and VYD2311 Pipeline Focus
Key Takeaways
- Invivyd is expected to report its third-quarter 2026 results in early-to-mid November, with consensus estimates calling for a loss of roughly $0.11 per share on revenue near $15 million.
- Investors will be watching whether net product revenue for PEMGARDA, the company's COVID-19 prevention antibody, sustains its momentum after growing 22% year over year in the first quarter.
- The pivotal DECLARATION study of lead pipeline candidate VYD2311 is the central watch item, with topline data anticipated around the Q3 2026 timeframe.
- Elevated research and development (R&D) spending tied to clinical trials has widened quarterly losses and remains a key swing factor for the bottom line.
Placing the Earnings in Context
Invivyd, Inc. (IVVD) is a biopharmaceutical company focused on antibody-based protection against serious viral diseases, beginning with SARS-CoV-2, the virus that causes COVID-19. The company's commercial product, PEMGARDA (pemivibart), is a monoclonal antibody (mAb) used for pre-exposure prophylaxis, or prevention before exposure, of COVID-19 in certain immunocompromised adults. The upcoming report carries heightened significance because the company is simultaneously trying to grow its only marketed product while advancing VYD2311, a next-generation intramuscular antibody candidate, through a pivotal Phase 3 trial. Prior quarters have shown steady revenue gains paired with widening losses, so investors will look for evidence that commercial momentum is translating toward a more sustainable financial path. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What the Numbers Are Expected to Show
Analysts expect Invivyd to report a net loss of approximately $0.11 per share for the third quarter of 2026, with consensus revenue near $15.0 million, according to market data aggregators. Estimates vary modestly across sources, with some pointing to a per-share loss closer to $0.13 to $0.14 and revenue in the $15.0 million to $15.6 million range. For comparison, in the third quarter of 2025 the company reported a loss of $0.06 per share on revenue of $13.13 million, meaning the consensus implies notable revenue growth alongside a wider per-share loss year over year.
Recent history offers caution. In the second quarter of 2026, Invivyd posted a loss of $0.14 per share and revenue of $14.29 million, both missing consensus, as heavy spending on the DECLARATION clinical program weighed on results. The company has beaten earnings per share (EPS) estimates in only a handful of its recent quarters, making cost discipline and clinical spending a central focus heading into this print. From what I see, tracking these trends with tools like Tickeron’s AI Trend Prediction Engine helps put the variability into perspective.
Market Reaction and Investor Sentiment
Sentiment heading into the report is cautious. Invivyd shares have struggled in 2026, trading well below their 52-week highs and near lower levels of their range, reflecting investor uncertainty about both the durability of PEMGARDA demand and the heavy costs of the VYD2311 development program. The stock has also shown sensitivity to earnings misses in the past, with prior shortfalls tied to revenue and EPS estimates preceding share declines. Heading into this update, the market's attention is split between the quarterly financials and any commentary or data on VYD2311, which many view as the more consequential long-term driver for the company.
Forward Outlook and Key Factors to Monitor
The single most important catalyst for Invivyd is the progress of VYD2311. The candidate is being evaluated in the DECLARATION pivotal study, and topline data has been anticipated around the third quarter of 2026. Any readout or updated timing on this trial could have a larger impact on the share price than the quarterly numbers themselves.
On the commercial side, investors should monitor PEMGARDA's revenue trajectory and whether the company can keep growing sales amid declining broader vaccine utilization. Management has argued that SARS-CoV-2 remains an ever-present threat with periodic waves, which could support steadier demand than a typical seasonal respiratory product.
Finally, watch the expense line. Research and development spending has surged as the company funds its clinical programs, and selling, general and administrative costs have also risen ahead of a potential VYD2311 launch. Invivyd's cash position remains an important buffer, and investors will look for signs that spending normalizes once key trials conclude. As always, no single quarter defines the story, but this report and its accompanying commentary could sharpen the market's view of both the near-term financial path and the long-term pipeline opportunity.
Exploring Tickeron’s AI Tools for Deeper Analysis
In my own review of names like this, I often turn to Tickeron’s AI Screener to quickly filter peers by fundamentals, technical patterns, and AI signals. It helps surface comparable ideas without manual effort and gives a clearer sense of where a stock stands relative to its sector. I’ve found it especially useful when weighing clinical-stage biotechs against broader market trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for IVVD turns negative, indicating new downward trend
IVVD saw its Momentum Indicator move below the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 72 similar instances where the indicator turned negative. In 66 of the 72 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
IVVD moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IVVD crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVVD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IVVD entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IVVD's RSI Indicator exited the oversold zone, 40 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 59 cases where IVVD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for IVVD just turned positive on November 02, 2026. Looking at past instances where IVVD's MACD turned positive, the stock continued to rise in 34 of 40 cases over the following month. The odds of a continued upward trend are 85%.
Following a +4.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVVD advanced for three days, in 186 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.916) is normal, around the industry mean (3.482). P/E Ratio (-1.816) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.722) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. IVVD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVVD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement